COORDINATED PROGRAM DEVELOPMENT, LLC — Department of Health and Human Services SBIR Phase II: Aminoglycosides are an important class of antibiotics for the treatment of aerobic, gram-n
COORDINATED PROGRAM DEVELOPMENT, LLC — SBIR Phase II award from Department of Health and Human Services.
- Amount
- $744,075
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- NAICS
- —
- Place of performance
- NJ
- Period
- —
Description
Aminoglycosides are an important class of antibiotics for the treatment of aerobic, gram-negative bacteria (Pseudomonas, Acinetobacter, Enterobacter) and mycobacteria (Mycobacterium tuberculosis, M. avium), causes of serious co-infections in HIV-infected persons. Widespread use of aminoglycosides has been limited due to their toxicity (nephrotoxicity and ototoxicity) and inconvenient route of administration (intravenous or intramuscular); the adverse effects are related to plasma drug levels. For example, use of amikacin for first-line therapy is limited due to poor oral absorption, a short half-life, and serious renal and auditory toxicities which necessitate frequent intravenous administration, with concomitant monitoring of drug levels to ensure that thelevels in plasma remain within a narrow therapeutic window.